Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

Can the drugmaker justify its valuation?

Shares of Krystal Biotech KRYS have risen 16% over the past three months against the industry’s 9.4% decline, driven by ...

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry ...

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.

The biotech sector is one that's become red-hot, at least in recent years. After around a decade of stagnation, investors appear to be intent on increasing their exposure to top biotech names in the ...

The biotech sector has always held a special appeal for risk-tolerant investors. While these companies face high overhead in the form of towering R&D costs and long lead times for bringing new ...

A clinical trial update wiped out billions in the French company's market cap and raised questions over a potential takeover.

If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that ...

The ASX biotech sector lost about 7% of its value in May. But not every stock lagged and hopes for a rebound abound.

The outbreak of Hantavirus on a cruise ship has led to biotech and pharmaceutical stocks surging on reports of firms developing vaccines.